Antibiotic combination for serious abdominal infections
Treatments studied
Part of Infections clinical trials.
This trial tests a new antibiotic combination (meropenem and pralurbactam) for people with serious infections inside the belly (abdomen). It aims to see if this treatment is safe and works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a serious infection inside your belly (abdomen) that is confirmed or highly suspected.
- You have signs of infection, such as fever, low blood pressure, belly pain, nausea, vomiting, or a belly mass.
- You are not allergic to penicillin, cephalosporins, or similar antibiotics.
- Your kidneys work well enough (creatinine clearance greater than 50 mL/min).
- You are willing to use effective birth control during the study and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial is checking how well a combination of two antibiotics, aztreonam and avibactam, works in patients who have a specific type of drug-resistant bacterial infection in the belly or lungs. It aims to offer a new treatment option for infections that are hard to cure.
This trial tests a new antibiotic combo (ertapenem-zidebactam) against an existing one (ceftazidime-avibactam) for serious urinary tract or kidney infections in hospitalized patients. It aims to see if the new drug is as effective and safe.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
Hear when a new Intra-Abdominal Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.